Raphael Pharmaceutical Inc. Retained Earnings
Raphael Pharmaceutical Inc. (RAPH) had Retained Earnings of -$10.62 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$10.62M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$10.40M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$10.17M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$9.89M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$10.62M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$10.40M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$10.17M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | -$9.89M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$9.64M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$9.32M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$8.89M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$8.43M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$8.11M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$7.86M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$7.37M 10-K · filed 2025-03-31 | -$7.31M 10-K · filed 2024-03-28 |
| 2023-09-30 | -$7.43M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$6.71M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | -$6.29M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$6.03M 10-K · filed 2024-03-28 | -$6.03M 10-K · filed 2023-03-24 |
| 2022-09-30 | -$4.92M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$3.48M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | -$2.85M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$2.67M 10-K/A · filed 2023-05-25 | |
| 2021-09-30 | -$2.10M 10-Q · filed 2021-11-16 | |
| 2020-12-31 | -$1.04M 10-K · filed 2022-03-30 |